ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 16
Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.